Hospital Acquired Infections Therapeutic Market Size & Share Report, Growth, Trends, 2032

The Hospital Acquired Infections Therapeutic Market is set for a quick growth over the forecast period. In terms of revenue, the global Hospital Acquired Infections Therapeutic Market accounted for USD 10.3 Billion in 2019 and is expected to reach USD 12.5 Billion by 2026 at a CAGR of 2.4 % during the forecast period.

Request Free Sample

Global Hospital Acquired Infections Therapeutic Market: Overview

Hospital Acquired Infections Therapeutic Market is also known as Healthcare-associated Infections. It is one of the leading causes of death worldwide. It can be acquired in hospital, nursing home, rehabilitation facility, outpatient clinic, etc. Hospital Acquired Infections (HAIs) are caused due to fungal, viral, and bacterial infections. Poor maintenance of hygiene and growing complacency among healthcare workers are the factors leading to HAIs.

Global Hospital Acquired Infections Therapeutic Market: Growth Factors

Increase in number of hospital admitted patients and improved diagnostics capable of differentiating strains of microbes has resulted in increase of Hospital Acquired Infections worldwide. The rising geriatric population, which is more vulnerable to such ailments, is also driving the market growth. The rise in number of pipeline drugs specifically developing for the hospital acquired infections and an increase in R&D investments expected to boost the market growth over the forecast period. Improvement in the healthcare infrastructure is also likely to boost the market of Hospital Acquired Infections Therapeutic globally.

Global Hospital Acquired Infections Therapeutic Market: Report Scope:

Global Hospital Acquired Infections Therapeutic Market: Segmentation

The Hospital Acquired Infections Therapeutic Market is segmented based on drug class, infection type and region.

On the basis of drug class, the Hospital Acquired Infections Therapeutic Market is segmented into Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs. In 2019, the Antibacterial Drugs dominated the market as most of the cases were caused due to bacteria and thus treated with antibacterial drugs.

Based on infection type, the Hospital Acquired Infections Therapeutic Market is bifurcated into Urinary Tract Infections, Ventilator-associated Pneumonia, Surgical Site Infections, Bloodstream Infections, Other Hospital Infections. In 2019, the Surgical Site Infections held the maximum number of shares due to the rising number of surgical procedures and cases.

Global Hospital Acquired Infections Therapeutic Market: Regional Analysis

Europe dominated the market for Hospital Acquired Infections due to the high prevalence of HAIs in European countries and increasing approvals and launch of novel HAI therapeutic drugs in the region. Furthermore, higher accessibility of novel hospital-acquired infection therapeutics in the European is further expected to drive the growth of the region.

In Asia Pacific, the market for HAIs therapeutics is anticipated to show significant growth during the forecast period due to factors such as increasing prevalence of chronic diseases in emerging economies such as India and China which has led to increased hospitalizations.

Global Hospital Acquired Infections Therapeutic Market: Competitive Players

The key players are forming various strategies such as product launches, collaborations, product development to gain competitive advantage in the market.

• Merck & Co. Inc.
• Pfizer Inc.
• Bayer AG
• GlaxoSmithKline Plc.
• Daiichi Sankyo Company Limited
• AbbVie Inc.
• Abbott Laboratories
• F. Hoffmann-La Roche Ltd.
• Cubist Pharmaceuticals Inc.
• Allergan Plc.
• among others

The global Hospital Acquired Infections Therapeutic Market is segmented as follows:

By Drug Class

• Antibacterial Drugs
• Antiviral Drugs
• Antifungal Drugs

By Infection Type

• Urinary Tract Infections
• Ventilator-associated Pneumonia
• Surgical Site Infections
• Bloodstream Infections
• Other Hospital Infection

By Region

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa